Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a leading biopharmaceutical company dedicated to developing innovative treatments for patients with serious and life-threatening diseases. Our recent milestone includes the FDA approval of RELYVRIO™ (sodium phenylbutyrate and taurursodiol) for the treatment of ALS in adults in the U.S. This breakthrough medication, previously known as AMX0035, has the potential to significantly improve the lives of those affected by this devastating condition. In addition to our commitment to developing groundbreaking therapies, Amylyx is also focused on ensuring access to these treatments for patients in need. We have signed a Letter of Intent with the pCPA to secure public coverage of our product ALBRIOZA™ for ALS treatment in Canada. We are actively working with federal, provincial, and territorial drug plans to ensure that eligible Canadians with ALS have access to this life-changing medication. At Amylyx, we are driven by our passion for helping patients and our dedication to making a meaningful impact in the field of healthcare. Our unique culture fosters collaboration, transparency, and a patient-centric approach to drug development. We understand the urgency of finding effective treatments for ALS and other serious diseases, and we are committed to pushing the boundaries of medical research to deliver innovative solutions to those in need. Our team is comprised of dedicated individuals who are truly passionate about making a difference in the lives of patients. We understand the challenges faced by those living with ALS and other debilitating conditions, and we are determined to overcome these obstacles through our relentless pursuit of discovery and innovation. At Amylyx Pharmaceuticals, we believe in putting patients first, and we are committed to working tirelessly to bring hope and healing to those who need it most. Join us on our journey to transform the future of healthcare and make a lasting impact on the lives of patients around the world.